Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Aggressive lymphoma at ASH 2012: new standards and new perspectives

Aggressive lymphoma at ASH 2012: new standards and new perspectives Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Aggressive lymphoma at ASH 2012: new standards and new perspectives

Loading next page...
 
/lp/springer-journals/aggressive-lymphoma-at-ash-2012-new-standards-and-new-perspectives-C079uKAJl5

References (15)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0086-8
Publisher site
See Article on Publisher Site

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 18, 2013

There are no references for this article.